Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gapped up prior to trading on Monday . The stock had previously closed at $1.80, but opened at $1.75. BioCryst Pharmaceuticals shares last traded at $1.82, with a volume of 194,248 shares trading hands.
A number of equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday, October 31st. ValuEngine lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 6th. BidaskClub lowered shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, October 4th. Finally, Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $8.94.
The company has a quick ratio of 1.43, a current ratio of 0.96 and a debt-to-equity ratio of 2.38. The firm has a market capitalization of $175.04 million, a PE ratio of -1.77 and a beta of 1.86. The firm’s fifty day simple moving average is $2.38 and its 200-day simple moving average is $3.53.
Institutional investors and hedge funds have recently made changes to their positions in the business. UBS Asset Management Americas Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 7.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 65,958 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 4,803 shares during the period. Bank of Montreal Can grew its position in BioCryst Pharmaceuticals by 921.9% in the second quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 9,219 shares in the last quarter. Commonwealth Equity Services LLC grew its position in BioCryst Pharmaceuticals by 22.8% in the second quarter. Commonwealth Equity Services LLC now owns 53,230 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 9,900 shares in the last quarter. Quantamental Technologies LLC acquired a new stake in BioCryst Pharmaceuticals in the second quarter valued at approximately $43,000. Finally, Rhumbline Advisers grew its position in BioCryst Pharmaceuticals by 8.4% in the third quarter. Rhumbline Advisers now owns 175,062 shares of the biotechnology company’s stock valued at $502,000 after acquiring an additional 13,631 shares in the last quarter. 92.40% of the stock is currently owned by institutional investors.
BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Read More: Depreciation
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.